Another study brought to you by…..Merck and company
Laurie Barclay, MD
July 29, 2010 — Human papillomavirus (HPV) quadrivalent vaccine offers prolonged protection against anogenital warts and low-grade cervical, vulvar, and vaginal neoplasias, according to the results of 2 randomized controlled trials reported in the July 21 issue of the BMJ.
Latest Efficacy Data Presented
“This study gives us the latest and most comprehensive data on the efficacy of the quadrivalent HPV vaccine in protecting against low grade precancerous lesions of the cervical, vulva and vagina, and anogenital warts in young women, over a longer period of follow-up than previously reported,” Karen Canfell, PhD, a cancer epidemiologist at the Cancer Epidemiology Research Unit Cancer Council in New South Wales, Sydney, Australia, told Medscape Medical News when asked for independent comment. “The results confirm that the quadrivalent vaccine is highly effective in protecting against low grade disease and anogenital warts directly related to the vaccine-included HPV types in women who have not previously been exposed to these types, and this protection is sustained for at least 4 years. However, in the case of cervical low grade lesions, the protective effect against the entire spectrum of lesions is lower, because these can be caused by a variety of high risk and low risk HPV types.”
The goal of the FUTURE I/II Study, by Joakim Dillner, from Lund University and Malmö University Hospital in Malmö, Sweden, and colleagues, was to determine the prophylactic efficacy of HPV quadrivalent vaccine in preventing low-grade intraepithelial neoplasias and condyloma acuminata (anogenital warts). FUTURE I (protocol 013) and FUTURE II (protocol 015) were designed to last for 4 years; this analysis was from final study data with follow-up of 42 months.
At primary care and university or hospital-associated medical centers in 24 countries and territories worldwide, 17,622 women aged 16 to 26 years were enrolled from December 2001 through May 2003. Pregnant women and those with a history of more than 4 sexual partners in their lifetime or abnormal cervical smear test results were excluded.
“Data are pooled from 2 randomized controlled trials of quadrivalent vaccine conducted in over 17,000 women aged 16-26 years, and there was an average of about 4 years of follow-up information,” Dr. Canfell said.
Merck & Co supported this study, employs 9 of the study authors, and has various financial relationships with some of the other study authors. A complete description of other various financial relationships is available in the original article. Dr. Canfell has disclosed no relevant financial relationships.
BMJ. 2010;340:c3493. Abstract